Abeona Therapeutics Inc vs Cardinal Health Inc — how do they compare? Abeona Therapeutics Inc trades at $7.57 (market cap $421.19M), while Cardinal Health Inc trades at $240 (market cap $55.88B). The key difference: Cardinal Health Inc is far larger — about 132.7× Abeona Therapeutics Inc's market cap, and Cardinal Health Inc pays a 0.86% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CAH | |
|---|---|---|
Market Cap | $421.19M | $55.88B |
Sector | Health | Health |
52-Week High | $7.45 | $240.26 |
52-Week Low | $4.17 | $146.04 |
Enterprise Value | $276.10M | $59.91B |
Dividend Yield | — | 0.86% |
Trailing returns across standard periods
Latest headlines on both assets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →